Background The comparative effectiveness of treatments for prostate cancer that is detected
by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active …

Background Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …

Background Robust data on patient-reported outcome measures comparing treatments for
clinically localized prostate cancer are lacking. We investigated the effects of active monitoring…

… Oxley, Richard Martin, Jenny Donovan, David Neal, Freddie Hamdy, Emma Turner, and J.
Athene Lane; the data monitoring committee: Lars Holmberg (chair), Robert Pickard, Simon …

… Derek J Rosario senior lecturer in cancer studies1, J Athene Lane senior research fellow2,
Chris Metcalfe senior lecturer in medical statistics2, Jenny L Donovan professor of social …

Background There is no conclusive evidence that screening based on serum prostate-specific
antigen (PSA) tests decreases prostate-cancer mortality. Since its introduction in the USA …

Background Prostate cancer is a major public health problem with considerable uncertainties
about the effectiveness of population screening and treatment options. We report the study …

Background Long-term patient-reported outcomes are needed to inform treatment decisions
for localized prostate cancer. Methods Patient-reported outcomes of 1643 randomly …

Background: Disturbed folate metabolism is associated with an increased risk of some cancers.
Our objective was to determine whether blood levels of folate, vitamin B 12 , and related …

Randomised controlled trials (RCTs) represent the gold standard methodology for determining
effectiveness of healthcare interventions. Poor recruitment to RCTs can threaten external …